Reviews in Urology

Our goal is to be there for every person who hears the words, "You have prostate cancer," by providing information, support, and resources to support both the patient and their loved ones. Our VP of Patient Programs & Education, Shelby Moneer, MS, CHES, recently sat down with Benjamin Lowentritt of Chesapeake Urology Associates to discuss key advancements in prostate cancer education, personalized patient support, our advocacy efforts, and more. Tune in now to learn about our latest resources and initiatives! https://lnkd.in/etW5gEZU #ZEROProstateCancer #ProstateCancerAwareness

Issue 3 of Reviews in Urology?(RIU) is LIVE!?View the digital?publication here: https://lnkd.in/eSerZHA2 ? This issue will include insights on topics such as:? - Urological health - Pediatric urology - Prostate, kidney, and bladder cancer - The business of urology - Technology/AI innovations - Patient navigation? ? In?collaboration with Specialty Networks and LUGPA, this quarterly peer-reviewed publication?is designed to review the latest?advances in the diagnosis and treatment of a wide range?of urological conditions to help the busy, practicing?urologist keep up to date with the rapidly evolving field?of urology. Stay connected with?RIU?by downloading the mobile app: - App Store: https://lnkd.in/eXaPGGwD - Google?Play: https://lnkd.in/e4dAmRXZ

Featured article of the week! Authored by Dr. Paul Dato and Dr. Rana McKay, this review describes the results of the ARASENS trial and the implications for care of men with metastatic HSPC to support oncologists’ and urologists’ clinical decision-making. This article also includes an Author Discussion video for further details on the review. https://lnkd.in/eQu7quaQ LUGPA Specialty Networks

Specialty Networks extends our deepest gratitude to the dedicated members of UroGPO (A Specialty Networks Company), representing more than 800 independent Urology practices in 49 states. As we observe Urology Awareness Month this September, we celebrate the incredible work of our members, industry partners, and the broader community.

Featured article of the week! Since its inception, IsoPSA has been shown in various contexts to predict clinically significant prostate cancer more accurately than standard PSA testing. This review?by Aidan Kennedy, MD and Jason Hafron,?describes key contemporary findings concerning IsoPSA as a screening tool for diagnosing clinically significant prostate cancer and how IsoPSA can be incorporated into everyday practice. Read the full article here: https://lnkd.in/gWFV2mAZ

Appreciate RIU publishing articles highlighting urology APP practice. The workforce challenges facing urology are daunting to say the least. APPs are certainly part of the solution, however, it will take a collaborative effort by all providing urological care to develop workforce shortage solutions. I hope this article is an invitation for others to share their ideas through RIU, society meetings, or wherever meaningful discussions can occur that lead to effective and sustainable workforce solutions.

Featured article of the week! In this article, Kenneth Mitchell discusses the role of Advanced Practice Providers (APPs) to meet the growing demand for urologic care amidst a declining workforce, as well as how RIU can help develop global solutions for practices with urology APPs. Read the full article here: https://lnkd.in/eMvxj4px ?

Featured article of the week! Written by Michael J Shannon and Sandip Prasad,?this article?provides tips for Urologists who are?integrating JELMYTO (Mitomycin) for Pyelocalyceal Solution into their practice, including:?a breakdown of the current need for alternatives to surgical intervention, background information of mitomycin gel in the treatment of UTUC, and how to incorporate Mitomycin Gel into clinical practice. ? Click here to read the full article: https://lnkd.in/eQURSs-f?

Featured article of the week! Written by Specialty Networks members Caroline Branch, Daniel Canter, and Gautam Jayram; Management of Adverse Events From Checkpoint Inhibitors in Urologic Practice: Where Are We Today? Members of the urology community are becoming increasingly interested in being more active participants in urologic cancer care. Recent survey data from independent group urology meetings have suggested that 20% of large community-based urology groups are currently administering checkpoint inhibitor therapies in their practice, and up to 50% are interested in doing so in the near future. Read the full article here: https://lnkd.in/eJ5Qdvjd

Issue 2 of Reviews in Urology?(RIU) is now LIVE!?The issue will include insights on topics such as:? - Urological health - Prostate, kidney, and bladder cancer - The business of urology - Health policy - Technology/AI innovations - Patient navigation? - News for advanced practice providers - Coding/reimbursement trends In?collaboration with Specialty Networks and LUGPA, this quarterly peer-reviewed publication?is designed to review the latest?advances in the diagnosis and treatment of a wide range?of urological conditions to help the busy, practicing?urologist keep up to date with the rapidly evolving field?of urology. View the?publication here: https://lnkd.in/eqS_DGwM Stay connected with?RIU?by downloading the mobile app: - App Store: https://lnkd.in/eXaPGGwD? - Google?Play: https://lnkd.in/e4dAmRXZ